The Longevity Reality Radar
46 approaches, rated by evidence.

Psilocybin for brain aging

Psilocybin for brain aging & neurodegeneration. Brain & neurodegeneration. Reviewed Jul 2026.

A single Alzheimer's case report and preliminary lab data, not a basis for treating brain aging.

Stage
Speculative
Rung: Experimental. Animal, lab or theoretical. Years away, if ever.
Evidence grade
D
one case report
Animal or lab only, single pilot, or case reports. How grades work.

What it is

The psychedelic compound being explored for neuroplasticity, depression, and — at the frontier — cognition in dementia and even lifespan.

The evidence

Early signals only: a striking single Alzheimer's case report of temporary improvement, plus preliminary lab data hinting at lifespan effects. Anecdote and early science — not ready to guide human aging treatment.

What you can do today

Not available for this use, and years away if it arrives at all. Anything sold today with this claim is not backed by human evidence for it.

Sources

  • Coverage, not a sourcex.com

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Brain & neurodegeneration

All 5 in Brain & neurodegeneration.

  • Lecanemab and donanemabGrade A, outcome RCTs. Approved.Slows cognitive decline by about 27 to 35% in early Alzheimer's, which is not a cure, and brain swelling or bleeding is a real risk.
  • 40 Hz light and sound for Alzheimer'sGrade C, small human trial. Phase 3, no results yet.Strong mouse data and one small human feasibility trial, but the Phase 3 has not reported and human efficacy is not established.
  • GLP-1 drugs for brain healthGrade C, emerging data. Phase 2/3.Early signals of better memory, but large trials are still running and no brain benefit is proven.
  • Stem-cell therapy for Parkinson'sGrade C, small cohorts. Phase 1/2, conditional approval in Japan.Motor symptoms eased or stabilised for up to two years in small cohorts, with no large randomised results yet.